- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00402116
Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients
Phase 1/2 Study of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
There will be 2 phases in this study. Patients will either be enrolled to the first phase or to the second phase, depending upon when they enroll into the study.
The first phase of this study is done to evaluate the safety of enzastaurin in patients. This is done by gradually increasing the dose of the drug in small groups of patients and watching closely for side effects.
In the second phase of the study, the dose determined to be safe will be used with temozolomide during and following radiation therapy to see if the combination can help patients with brain tumors live longer.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must have a histologically confirmed diagnosis of intracranial glioblastoma multiforme (GBM) or gliosarcoma (GS).
- Biopsy or resection must have been performed no more than 5 weeks prior to treatment.
- An MRI or CT scan must be obtained within 14 days prior to treatment.
- Patients must not have received prior drug therapy for brain tumors.
- Patients must have adequate organ function demonstrated by lab tests within 14 days prior to treatment.
Exclusion Criteria:
- Patients will be excluded if unable to swallow tablets.
- Patients will be excluded if unable to discontinue use of enzyme inducing antiepileptic drugs or have been off of these agents less than 2 weeks prior to treatment (i.e. phenytoin (Dilantin®), carbamazepine, etc.).
- Patients will be excluded if have active infection.
- Patients will be excluded if have a significant medical illness that, in the investigator's opinion, cannot be adequately controlled with appropriate therapy or would compromise the patient's ability to tolerate this therapy.
- Patients will be excluded if they have concurrent therapy with an anticoagulant. If the patient requires anticoagulant therapy after starting treatment, the patient may remain on study but should be monitored carefully.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: A
The Phase 1 consisted of the dose escalation of enzastaurin in 2 cohorts of up to 6 patients to assess maximum tolerated dose (MTD).
Cohort 1 = radiotherapy/enzastaurin 250 mg per day/temozolomide 75 mg/m^2 therapy.
The 6 initial cohort patients were clinically evaluated for dose-limiting toxicities (DLT).
If no more than 1 of 6 patients experienced a DLT or tumor progression, patients continued 1 complete adjuvant enzastaurin/temozolomide 28-day cycle.
If there was no significant toxicity after the first adjuvant cycle, participants received subsequent adjuvant enzastaurin/temozolomide cycles.
If no more than 1 of the 6 initial cohort participants treated at 250 mg of enzastaurin experienced a DLT during radiotherapy and the first adjuvant cycle, up to 6 more participants could be entered at 500 mg of enzastaurin.
The Phase 2, using the MTD determined in the Phase 1 (250 mg), evaluated the combination's safety and measured OS.
|
Phase 1 - 250 mg Cohort 1 with one dose escalation allowed to 500 mg for Cohort 2, oral, daily, 6 weeks then twelve 28 day cycles Phase 2 - Phase 1 established dose, oral, daily, 6 weeks then twelve 28 day cycles
Other Names:
75 milligrams per meter squared (mg/m^2), oral, daily, 6 weeks then 200 mg/m^2, oral, daily, twelve 28 day cycles
1.8-2.0
Gy x 30 fractions, 5 days/week, for 6 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1- Determination of the Maximum Tolerated Dose (MTD) of Enzastaurin
Time Frame: Until MTD can be determined (up to 12 cycles, 28 days per cycle)
|
Phase 1- dose escalation of enzastaurin in 2 cohorts up to 6 participants each in order to assess MTD.
After radiation/enzastaurin 250 mg per day/temozolomide 75 mg/m^2 therapy, if no more than 1 of 6 patients experienced a dose-limiting toxicity (DLT) or tumor progression, participants completed one 28-day cycle.
If no significant toxicity after the first cycle, participants received subsequent cycles.
If no more than 1 of the 6 patients treated at 250 mg of enzastaurin experienced a DLT, up to 6 more patients could be entered at escalated dose cohort of enzastaurin (500 mg).
|
Until MTD can be determined (up to 12 cycles, 28 days per cycle)
|
Phase 1 and Phase 2 - Overall Survival (OS)
Time Frame: Baseline to death from any cause (Up to 48 weeks)
|
OS is the time from surgical diagnosis to the date of death from any cause.
For participants who were alive, OS was censored at the last contact.
|
Baseline to death from any cause (Up to 48 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1 - Number of Participants With Adverse Events (AEs)
Time Frame: Every cycle (up to 12 cycles, 28 days per cycle)
|
Summaries of serious AEs (SAEs) and all other non-serious AEs are located in the Reported Adverse Event Module.
|
Every cycle (up to 12 cycles, 28 days per cycle)
|
Phase 1 and 2: Association Between Biomarkers and Clinical Outcome
Time Frame: Baseline, Cycle 2, end of study (up to 12 cycles, 28 days per cycle)
|
Phosphorylated-S6 (pS6) ribosomal protein is a biomarker that's being investigated as a potential marker for clinical outcome using 2211 or 2215 antibody to pS6.
Reported here are the hazard ratios and 95% confidence intervals (CIs) for participants for whom an pS6 immunohistochemistry (IHC) score was available.
The IHC assays were scored using a 0 to +3 scoring system (no positive staining was scored 0; at least 25% immunoreactivity of cells was scored +1; 26% to 75% was scored +2; and 76% or greater was scored +3).
Hazard ratio (HR) > 1 indicates worse outcome for that IHC score.
|
Baseline, Cycle 2, end of study (up to 12 cycles, 28 days per cycle)
|
Phase 1 - Response Rate With Macdonald Criteria
Time Frame: Baseline, following radiation, every other cycle (up to 12 cycles, 28 days per cycle)
|
Response categories: complete response (CR): disappearance of all enhancing tumor on consecutive magnetic resonance imaging (MRI) scans at least 1 month apart, off steroids, and neurologically stable or improved.
Partial response (PR): 50% reduction in size of enhancing tumor on consecutive MRI scans at least 1 month apart, steroids stable or reduced, and neurologically stable or improved.
Progressive disease (PD): >25% increase in size of enhancing tumor or any new tumor on MRI scans, or neurologically worse, and steroids stable or increased.
Stable disease (SD): all other situations.
|
Baseline, following radiation, every other cycle (up to 12 cycles, 28 days per cycle)
|
Phase 2 - Number of Participants With Adverse Events (AEs)
Time Frame: Every cycle (28 days per cycle)
|
Summaries of serious AEs (SAEs) and all other non-serious AEs are located in the Reported Adverse Event Module.
|
Every cycle (28 days per cycle)
|
Number of Participants Undergoing Magnetic Resonance Imaging/Magnetic Resonance Spectroscopy (MRI/MRS) for Clinical Evaluation at Baseline
Time Frame: Each radiologic assessment (up to 12 cycles, 28 days per cycle)
|
Number of patients having MRI/MRS for clinical evaluation with baseline assessment.
|
Each radiologic assessment (up to 12 cycles, 28 days per cycle)
|
Phase 1 and 2 - Progression-Free Survival (PFS)
Time Frame: Baseline to measured progressive disease (up to 12 cycles, 28 days per cycle)
|
PFS was defined as the time from date of first dose to the first observation of disease progression, or death due to any cause.
|
Baseline to measured progressive disease (up to 12 cycles, 28 days per cycle)
|
Functional Assessment of Cancer Therapy - Brain (FACT-Br)
Time Frame: Every cycle (up to 12 cycles, 28 days per cycle)
|
Total FACT-Br score includes physical well-being, social/family well-being, emotional well-being, functional well-being and additional concerns related to brain tumors.
The score ranges 0 to 200, with a higher score representing better quality of life.
|
Every cycle (up to 12 cycles, 28 days per cycle)
|
M.D. Anderson Symptom Inventory - Brain Tumor (MDASI-BT)
Time Frame: Every cycle (up to 12 cycles, 28 days per cycle)
|
General and brain tumor-specific symptoms each assessed on a scale of 0 to 10, with a higher score representing higher symptom burden.
The 4 symptom scales reported as changing over the course of the study are listed here.
|
Every cycle (up to 12 cycles, 28 days per cycle)
|
Phase 1- Pharmacokinetics (PK): Maximum Observed Drug Concentration During 1 Dosing Interval at Steady State (Cmax,ss) for Enzastaurin, LY326020, and Total Analyte (Enzastaurin + LY326020) When Enzastaurin Administered With or Without Temozolomide
Time Frame: Cycle 1 Day 22, Cycle 2 Day 5, 28 days per Cycle
|
Cmax,ss was calculated using concentration versus time data of enzastaurin, LY326020, and Total Analyte (enzastaurin + LY326020) when 250 mg or 500 mg enzastaurin was administered alone or with 75 mg/m^2 temozolomide.
Data are reported as Geometric Mean and Geometric Coefficient of Variation (%).
|
Cycle 1 Day 22, Cycle 2 Day 5, 28 days per Cycle
|
Phase 1 and 2- Pharmacokinetics: Area Under the Concentration-Time Curve During 1 Dosing Interval at Steady State (AUCτ,ss) for Enzastaurin, LY326020 and Total Analyte (Enzastaurin + LY326020) When Enzastaurin Administered With or Without Temozolomide
Time Frame: Phase 1, Cycle 1 Day 22, Cycle 2 Day 5 of a 28 day Cycle; Phase 2, Cycle 1 Day 22 of a 28 day Cycle
|
AUCτ,ss was calculated using concentration versus time data of enzastaurin, LY326020, and total analyte (enzastaurin + LY326020).
Data are reported as Geometric Mean and Geometric Coefficient of Variation (%).
|
Phase 1, Cycle 1 Day 22, Cycle 2 Day 5 of a 28 day Cycle; Phase 2, Cycle 1 Day 22 of a 28 day Cycle
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Astrocytoma
- Glioma
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Glioblastoma
- Gliosarcoma
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Temozolomide
Other Study ID Numbers
- 9815
- H6Q-MC-S008 (OTHER: Eli Lilly and Company)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioblastoma
-
Celldex TherapeuticsCompletedGlioblastoma | Gliosarcoma | Recurrent Glioblastoma | Small Cell Glioblastoma | Giant Cell Glioblastoma | Glioblastoma With Oligodendroglial Component | Relapsed GlioblastomaUnited States
-
Juan M Garcia-GomezHospital Universitario 12 de Octubre; Hospital Clínico Universitario de ValenciaRecruitingGlioblastoma | Glioblastoma Multiforme | High Grade Glioma | Astrocytoma, Grade IV | Glioblastoma, IDH-mutant | Glioblastoma, IDH-wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) MutantSpain
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States, Belgium, Switzerland, Germany, Netherlands
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
-
Leland MethenyNational Cancer Institute (NCI)RecruitingGlioblastoma Multiforme | Supratentorial Gliosarcoma | Glioblastoma Multiforme, Adult | Supratentorial GlioblastomaUnited States
-
Northwestern UniversityAgenus Inc.; CarTheraRecruitingGlioblastoma Multiforme | Gliosarcoma | Newly Diagnosed Glioblastoma | Glioblastoma, Isocitric Dehydrogenase (IDH)-WildtypeUnited States
-
University Hospital, GenevaActive, not recruitingGlioblastoma Multiforme | Glioblastoma Multiforme of Brain | Glioma of Brain | Glioblastoma, AdultSwitzerland
-
Milton S. Hershey Medical CenterRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)RecruitingGlioblastoma | Astrocytoma | Recurrent Glioblastoma | MGMT-Unmethylated Glioblastoma | Glioblastoma, IDH-WildtypeUnited States
-
Milton S. Hershey Medical CenterNational Cancer Institute (NCI)RecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
Clinical Trials on enzastaurin
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompletedT-Cell Lymphoma | B-Cell LymphomaMexico, United States, Australia, Brazil, Peru
-
Eli Lilly and CompanyCompletedMantle-Cell LymphomaAustralia, France, Germany, Netherlands
-
Eli Lilly and CompanyCompletedNeoplasms | CancerUnited States
-
Eli Lilly and CompanyCompletedLymphoma, FollicularUnited States, Germany
-
Eli Lilly and CompanyCompletedLymphoma, Malignant | Solid TumorChina
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedOvarian Cancer | Primary Peritoneal Cavity CancerUnited States
-
Eli Lilly and CompanyCompletedLung CancerUnited States
-
National Cancer Institute (NCI)Terminated
-
Eli Lilly and CompanyCompletedNon Hodgkin LymphomaUnited States, China, Spain, Poland, Taiwan, Belgium, Japan, Germany, Puerto Rico, Australia, France, Sweden, Greece, Italy, India, Czechia, United Kingdom, Canada, Korea, Republic of, Mexico, Denmark, Portugal, Finland, Brazil, Hungary